Posters

    Assessment of Mitochondrial Function Following Long-Term Treatment of Human Bronchial Epithelial Cells with Total Particulate Matter from a candidate Modified-Risk Tobacco Product versus Cigarettes

    Van der Toorn, M.; Malińska, D.; Szymanski, J.; Walczak, J.; Prill, M.; Drabik, K.; Michalska, B.; Wojtala, A.; Patalas-Krawczyk, P.; Partyka, M.; Johne, S. Johne.; Sewer, A.; Guedj, E.; Luettich, K.; Peitsch, M. C.; Hoeng, J.; Wieckowski, M.; Szczepanowska, J.; Duszynski, J.

    Conference date
    Aug 24, 2017
    Conference name

    Tenth World Congress - Alternatives and Animal Use in the Life Sciences
    Link to more information
    Topic
    Summary

    No abstract available.

    Related Publications

    Systems Toxicology Assessment of Aerosol from a Candidate Modified Risk Tobacco Product Compared with Cigarette Smoke on Organotypic Gingival Epithelial Cultures

    Aerosol Chemistry Systems Toxicology

    Screening Of Aqueous Media Using GC×GC-TOF-MS

    Aerosol Chemistry Systems Toxicology

    Characterization of Aerosol Exposure, Metabolism and Pharmacokinetics for Toxicological Assessment Using In Vitro Organotypical Airway Models

    Aerosol Chemistry Systems Toxicology

    In Vitro Test Systems for Aerosols Toxicology Assessment - Characterization of Exposure, Metabolism and Kinetics

    Aerosol Chemistry Systems Toxicology

    Applicability of Different Soft Nucleophiles for the Screening of Reactive Metabolites upon Microsomal Activation of Furan Mixtures and Cigarette Smoke

    Aerosol Chemistry Systems Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.